News for ADXS Stock

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 Ayala Pharmaceuticals Announces Closing of Merger with Biosight Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023 Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022 Advaxis and Ayala Pharmaceuticals Complete Merger Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update Advaxis, Inc. Announces 1-for-80 Reverse Stock Split Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Advaxis Announces Publication of ADXS-PSA Data in The Oncologist Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones Advaxis Announces Acceptance for Trading on the OTCQX Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements Advaxis, Inc. Issues Letter to Stockholders Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd. Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit Advaxis and Biosight Announce Entry into Definitive Merger Agreement Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule Advaxis, Inc. Announces Closing of $9.2 Million Public Offering Advaxis, Inc. Announces Pricing of $8 Million Public Offering Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020 Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer Advaxis Announces Resignation of Chief Financial Officer Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020